[Treatment with cabergoline in Parkinson disease can cause heart damage. Continuous treatment requires clinical and echocardiographic check ups].
Lökk
Johan
J
Karolinska Universitetssjukhuset Huddinge. johan.lokk@karolinska.se
D000978:Antiparkinson Agents / Q000008:administration & dosage / Q000009:adverse effects*; D000077465:Cabergoline; D018491:Dopamine Agonists / Q000008:administration & dosage / Q000009:adverse effects*; D016903:Drug Monitoring; D004452:Echocardiography; D004873:Ergolines / Q000008:administration & dosage / Q000009:adverse effects*; D006349:Heart Valve Diseases / Q000139:chemically induced* / Q000000981:diagnostic imaging / Q000517:prevention & control; D006351:Heart Valves / Q000187:drug effects*; D006801:Humans; D010300:Parkinson Disease / Q000188:drug therapy*; D012307:Risk Factors
D000978:Antiparkinson Agents; D018491:Dopamine Agonists; D004873:Ergolines; D000077465:Cabergoline